Personeni, Nicola <br/><br/>
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.  [electronic resource] 

 -  Clinical colorectal cancer  Sep 2015 
 - 162-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0674 
<br/><br/><label>Standard No.: </label>10.1016/j.clcc.2015.02.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--adverse effects<br/>Cetuximab--administration & dosage<br/>Colorectal Neoplasms--drug therapy<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--adverse effects<br/>Gene Expression Regulation, Neoplastic<br/>Humans<br/>Leucovorin--adverse effects<br/>Male<br/>Middle Aged<br/>Mutation<br/>Neoplasm Metastasis<br/>PTEN Phosphohydrolase--genetics<br/>Prognosis<br/>Prospective Studies<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Proto-Oncogene Proteins c-met--genetics<br/>Proto-Oncogene Proteins p21(ras)--genetics